Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Tissue distribution of berberine and its metabolites after oral administration in rats.

Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, Fu J, Huang M, He CY, Shou JW, He WY, Wang Y, Jiang JD.

PLoS One. 2013 Oct 31;8(10):e77969. doi: 10.1371/journal.pone.0077969. eCollection 2013.

2.

Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes.

Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JD.

J Transl Med. 2011 May 15;9:62. doi: 10.1186/1479-5876-9-62.

3.

Excretion of berberine and its metabolites in oral administration in rats.

Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, Huang M, He CY, Chen SN, Zhao ZX, He WY, Wang Y, Jiang JD.

J Pharm Sci. 2013 Nov;102(11):4181-92. doi: 10.1002/jps.23718. Epub 2013 Sep 4.

PMID:
24006193
4.

Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.

Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, Wang GJ.

Drug Metab Dispos. 2010 Oct;38(10):1779-84. doi: 10.1124/dmd.110.033936. Epub 2010 Jul 15.

5.

Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry.

Wang W, Shen Q, Liang H, Hua C, Liu Y, Li F, Li Q.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 15;1031:172-80. doi: 10.1016/j.jchromb.2016.07.038. Epub 2016 Jul 18.

PMID:
27494281
6.

Pharmacokinetics, excretion of 8-cetylberberine and its main metabolites in rat urine.

Hu Y, Fan S, Liao X, Chen C, Su L, Li X.

J Pharm Biomed Anal. 2017 Jan 5;132:195-206. doi: 10.1016/j.jpba.2016.09.022. Epub 2016 Oct 15.

PMID:
27750103
7.
8.

Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism.

Zhou Y, He P, Liu A, Zhang L, Liu Y, Dai R.

Phytother Res. 2012 May;26(5):772-7. doi: 10.1002/ptr.3621. Epub 2011 Nov 24.

PMID:
22114028
9.

[Comparative study of pharmacokinetics and tissue distribution of 8-cetylberberine and berberine in rats].

Hu YL, Chen C, Zou ZY, Li XG, Ye XL.

Yao Xue Xue Bao. 2014 Nov;49(11):1582-7. Chinese.

PMID:
25757286
10.

Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma Coptidis extract and Wuji Wan formulas in rat using a UPLC-MS/MS method.

Chen Y, Li Y, Wang Y, Yang Q, Dong Y, Weng X, Zhu X, Wang Y, Gong Z, Zhang R.

Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):67-74. doi: 10.1007/s13318-014-0181-1. Epub 2014 Mar 1.

PMID:
24577954
12.

Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells.

Zhou Y, Cao S, Wang Y, Xu P, Yan J, Bin W, Qiu F, Kang N.

Fitoterapia. 2014 Jan;92:230-7. doi: 10.1016/j.fitote.2013.11.010. Epub 2013 Dec 7.

PMID:
24321576
13.

Simultaneous determination of berberine, palmatine and jatrorrhizine by liquid chromatography-tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of coptis-evodia herb couple.

Deng Y, Liao Q, Li S, Bi K, Pan B, Xie Z.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 1;863(2):195-205. doi: 10.1016/j.jchromb.2007.12.028. Epub 2008 Jan 21.

PMID:
18258496
14.

In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.

Yang N, Sun RB, Chen XL, Zhen L, Ge C, Zhao YQ, He J, Geng JL, Guo JH, Yu XY, Fei F, Feng SQ, Zhu XX, Wang HB, Fu FH, Aa JY, Wang GJ.

Acta Pharmacol Sin. 2017 Mar;38(3):351-361. doi: 10.1038/aps.2016.120. Epub 2017 Jan 2.

15.

Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.

Shan YQ, Ren G, Wang YX, Pang J, Zhao ZY, Yao J, You XF, Si SY, Song DQ, Kong WJ, Jiang JD.

Metabolism. 2013 Mar;62(3):446-56. doi: 10.1016/j.metabol.2012.09.009. Epub 2012 Oct 15.

PMID:
23079743
16.

Metabolites identification of berberine in rats using ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Wang K, Chai L, Feng X, Liu Z, Liu H, Ding L, Qiu F.

J Pharm Biomed Anal. 2017 May 30;139:73-86. doi: 10.1016/j.jpba.2017.02.038. Epub 2017 Feb 27.

PMID:
28279930
17.

Pharmacokinetics and tissue distribution of coptisine in rats after oral administration by liquid chromatography-mass spectrometry.

Yan Y, Zhang H, Zhang Z, Song J, Chen Y, Wang X, He Y, Qin H, Fang L, Du G.

Biomed Chromatogr. 2017 Jul;31(7). doi: 10.1002/bmc.3918. Epub 2017 Feb 1.

PMID:
27957743
18.

Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.

Xue M, Yang MX, Zhang W, Li XM, Gao DH, Ou ZM, Li ZP, Liu SH, Li XJ, Yang SY.

Int J Nanomedicine. 2013;8:4677-87. doi: 10.2147/IJN.S51262. Epub 2013 Dec 5.

19.

Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine.

Li YH, Li Y, Yang P, Kong WJ, You XF, Ren G, Deng HB, Wang YM, Wang YX, Jiang JD, Song DQ.

Bioorg Med Chem. 2010 Sep 1;18(17):6422-8. doi: 10.1016/j.bmc.2010.06.106. Epub 2010 Jul 30.

PMID:
20673726
20.

Pharmacokinetics and Brain Distribution and Metabolite Identification of Coptisine, a Protoberberine Alkaloid with Therapeutic Potential for CNS Disorders, in Rats.

Su J, Miao Q, Miao P, Zhao Y, Zhang Y, Chen N, Zhang Y, Ma S.

Biol Pharm Bull. 2015;38(10):1518-28. doi: 10.1248/bpb.b15-00293. Epub 2015 Jul 29.

Supplemental Content

Support Center